Skip to main content

Table 3 Cox proportional hazards regression analysis of 5-year distant disease-free survival according to St Gallen Molecular subtypes with luminal A as reference group

From: St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial

A. Univariable analysis
  Primary tumour Lymph node metastases
  FrequencyN(%) HR (95% CI) p-value FrequencyN (%) HR (95% CI) p-value
luminal A 45 (53) 1.0   38 (45) 1.0  
luminal B 17 (20) 2.8 (0.94-8.4) 0.064 23 (27) 3.1(1.0-9.5) 0.048
HER2-positive 11 (13) 4.5 (1.4-14) 0.011 11 (13) 7.3 (2.2-24) 0.001
Triple negative 12 (14) 5.9 (2.1-17) 0.001 13 (15) 4.6 (1.4-15) 0.011
B. Multivariable analysis
  Primary tumour 1 Lymph node metastases 1
  Frequency N (%) HR (95% CI) p -value Frequency N (%) HR (95% CI) p -value
luminal A 45 (53) 1.0   38 (45) 1.0  
luminal B 17 (20) 2.9 (0.96-8.8) 0.059 23 (27) 2.9 (0.92-9.0) 0.070
HER2-positive 11 (13) 3.1 (0.94-10) 0.063 11 (13) 4.8 (1.3-17) 0.016
Triple negative 12 (14) 4.6 (1.6-13) 0.006 13 (15) 3.9 (1.2-13) 0.029
  1. 1Adjusted for calendar-period (year at time of operation), age (years) and study regime (postmenopausal versus premenopausal study).
  2. Abbreviations: HER2 human epidermal growth factor receptor 2, HR hazard ratio, CI confidence interval, N number of patients, percentages are given within parenthesis.